{
  "authors": [],
  "date_download": "2022-08-16 17:13:07",
  "date_modify": "2022-08-16 17:13:07",
  "date_publish": "2022-08-05 11:02:41",
  "description": "Press release content from Business Wire. The AP news staff was not involved in its creation.",
  "filename": "article_technology-health-381ce11019934f3a90debd7e51370cce_1660669987.html",
  "image_url": "https://apnews.com/images/PaidContent3.png",
  "language": "en",
  "localpath": "C:\\Users\\USUARIO/news-please-repo//data/2022/08/16/apnews.com/article_technology-health-381ce11019934f3a90debd7e51370cce_1660669987.html",
  "title": "Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit",
  "title_page": "Pillar Biosciences to Participate in the 2022 UBS Genomics 2.0 and MedTech Innovations Summit",
  "title_rss": "NULL",
  "source_domain": "apnews.com",
  "maintext": "NATICK, Mass.--(BUSINESS WIRE)--Aug 5, 2022--\nPillar Biosciences , the leader in Decision Medicine�, which develops and distributes next-generation sequencing (NGS) products and technologies to localize testing and reduce time to treatment initiation and overall testing costs, today announced that Randy Pritchard, Chief Executive Officer, will participate in the �Liquid Biopsy in Clinical Practice� panel discussion at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California on Tuesday, August 9, 2022 at 7:00pm Eastern Time / 4:00pm Pacific Time. Randy Pritchard and Vincent Ricci, Chief Financial Officer, will also participate in investor meetings at the conference.\nAbout Pillar Biosciences\nPillar Biosciences is the leader in Decision Medicine�, which is the utilization of highly accurate and sensitive next-generation sequencing (NGS) testing technology to quickly and accurately generate data that optimizes selection of precision therapies for cancer patients, from tumor profiling to therapy selection, and recurrence monitoring. Pillar�s NGS testing solutions, including the FDA-approved oncoReveal� Dx Lung and Colon Cancer Assay, are powered by the Company�s proprietary SLIMamp� and PiVAT� technologies, which helps decentralize testing availability, reduces diagnostic costs and improves access and efficiency of complex NGS testing for clinicians, prescribers, and patients globally. The Company has more than 20 NGS testing products available in both IVD or RUO formats, and several others in various stages of development, including a pan-cancer oncoReveal� CDx assay, and two liquid biopsy offerings, one of which is focused on the detection of minimal residual disease (MRD). Pillar�s patented technologies have been shown to provide accurate and actionable clinical results in as little as 48 hours, which enables physicians to more quickly select appropriate targeted therapies and monitor the patient�s response. Pillar Biosciences has operations in Natick, MA and Shanghai, China. For more information, visit www.pillar-biosciences.com .\nADVERTISEMENT\nView source version on businesswire.com:https://www.businesswire.com/news/home/20220805005054/en/\nCONTACT: Investor:\nDawn Schottlandt\nArgot Partners\n212-600-1902\nPillar@argotpartners.comMedia:\nJoshua R. Mansbach\nArgot Partners\n212-600-1902\nPillar@argotpartners.com\nKEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS\nINDUSTRY KEYWORD: ONCOLOGY MEDICAL DEVICES HEALTH GENERAL HEALTH PHARMACEUTICAL BIOTECHNOLOGY\nSOURCE: Pillar Biosciences\nCopyright Business Wire 2022.\nPUB: 08/05/2022 07:00 AM/DISC: 08/05/2022 07:02 AM\nhttp://www.businesswire.com/news/home/20220805005054/en",
  "url": "https://apnews.com/article/technology-health-381ce11019934f3a90debd7e51370cce"
}